Karyopharm Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Karyopharm Therapeutics

04/05/2023 14:32

* Karyopharm Therapeutics Inc  KPTI.OQ  reported a quarterly
adjusted loss of 30 cents​​ per share for the quarter ended in
March. The mean expectation of nine analysts for the quarter was
for a loss of 37 cents per share.
    * Revenue fell 18.8% to $38.70 million from a year ago;
analysts
expected $36.60 million. 
    * Karyopharm Therapeutics Inc's reported EPS for the quarter
was a
loss of 30 cents​.
    * The mean earnings estimate of analysts had fallen by
about 15.1%
in the last three months.​ 
    * In the last 30 days, three analysts negatively revised
earnings
estimates 
    * Karyopharm Therapeutics Inc shares had fallen by 5.9% this
quarter and gained 7.6% so far this year.
    * The company reported a quarterly loss of $34.13 million.
    * Wall Street's median 12-month price target for Karyopharm
Therapeutics Inc is $8.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
4 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.37          -0.30          Beat
 Dec. 31 2022      -0.35          -0.43          Missed
 Sep. 30 2022      -0.57          -0.45          Beat
 Jun. 30 2022      -0.63          -0.62          Beat